Compare Okta, Inc. (OKTA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Okta, Inc. trades at $232.4 (market cap $38.50B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Okta, Inc. is far larger — about 2.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| OKTA | ZBH | |
|---|---|---|
Market Cap | $38.50B | $16.95B |
Volume | 2,479,621 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $220.21 | $103.98 |
52-Week Low | $62.93 | $79.58 |
Typical Hold Time | 44 Days | 89 Days |
Enterprise Value | $36.25B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA's stock trades at $232.13, up 6.48% in the last 24 hours, reflecting strong momentum. The technical outlook is bullish, with the price near resistance at $232. Recent earnings beats and a strategic focus on AI agent security, highlighted at the Oktane 2026 conference, support positive sentiment. However, valuation ratios like a P/E of 132.66 and P/S of 12.74 indicate a premium, while the company has only recently achieved profitability with a net income margin of 1.07% in 2025.
The outlook is cautiously optimistic, driven by revenue growth and AI positioning, but high valuation and competitive pressures pose risks. Analyst consensus is strongly bullish with a 73.58% buy rating, though the current price exceeds the consensus target of $201.30, suggesting near-term consolidation may occur. Investors should weigh growth potential against premium multiples and market volatility.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
